-
EP4237542
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4237542
| EP4237542 - GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 04.08.2023 Database last updated on 06.11.2024 | |
| Former | The international publication has been made Status updated on 07.05.2022 | ||
| Former | unknown Status updated on 01.12.2021 | Most recent event Tooltip | 05.01.2024 | Change: Validation states | published on 07.02.2024 [2024/06] | 05.01.2024 | Change - extension states | published on 07.02.2024 [2024/06] | Applicant(s) | For all designated states Sangamo Therapeutics, Inc. 7000 Marina Boulevard Brisbane, CA 94005 / US | [2023/36] | Inventor(s) | 01 /
FONG, Helen Brisbane, CA 94005 / US | 02 /
CONWAY, Anthony Brisbane, CA 94005 / US | 03 /
MENDEL, Matthew, C. Brisbane, CA 94005 / US | [2023/36] | Representative(s) | CMS Cameron McKenna Nabarro Olswang LLP Cannon Place 78 Cannon Street London EC4N 6AF / GB | [2023/36] | Application number, filing date | 21810847.0 | 28.10.2021 | [2023/36] | WO2021US57152 | Priority number, date | US202063106591P | 28.10.2020 Original published format: US 202063106591 P | [2023/36] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022094154 | Date: | 05.05.2022 | Language: | EN | [2022/18] | Type: | A1 Application with search report | No.: | EP4237542 | Date: | 06.09.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.05.2022 takes the place of the publication of the European patent application. | [2023/36] | Search report(s) | International search report - published on: | EP | 05.05.2022 | Classification | IPC: | C12N5/0783, C12N15/00 | [2023/36] | CPC: |
C12N5/0636 (EP,IL,US);
C12N5/0637 (EP,IL,KR,US);
A61K35/17 (KR);
A61K39/4611 (EP,IL,KR,US);
A61K39/4621 (EP,IL,US);
A61K39/46433 (EP,IL,US);
C12N2500/14 (EP,IL);
C12N2500/38 (EP,IL);
C12N2501/15 (EP,IL,KR,US);
C12N2501/2302 (EP,IL,KR,US);
C12N2501/2307 (EP,IL);
C12N2501/515 (EP,IL);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/36] | Title | German: | ERZEUGUNG VON CD4+-EFFEKTOR- UND REGULATORISCHEN T-ZELLEN AUS MENSCHLICHEN PLURIPOTENTEN STAMMZELLEN | [2023/36] | English: | GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS | [2023/36] | French: | GÉNÉRATION DE LYMPHOCYTES T EFFECTEURS ET RÉGULATEURS CD4+ À PARTIR DE CELLULES SOUCHES PLURIPOTENTES HUMAINES | [2023/36] | Entry into regional phase | 25.05.2023 | National basic fee paid | 25.05.2023 | Designation fee(s) paid | 25.05.2023 | Examination fee paid | Examination procedure | 25.05.2023 | Examination requested [2023/36] | 25.05.2023 | Date on which the examining division has become responsible | 20.12.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.10.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY]WO2019157597 (SUNNYBROOK RES INST [CA]); | [XP]WO2021092581 (SANGAMO THERAPEUTICS INC [US]); |